For research use only. Not for therapeutic Use.
Dipotassium glycyrrhizinate is a HMGB1 inhibitor, inhibits atopic dermatitis-related gene expression with anti-anti-inflammatory activity[1][2][3].
Dipotassium glycyrrhizinate (0-400 μM, 4 days) inhibits mRNA level of atopic dermatitis related genes (NELL2, CA2, AQP3, and HAS3 gene level) in IL‑4‑ and IL‑13‑induced keratinocytes[1].
Dipotassium glycyrrhizinate (0-400 μM, 4 days) partially repaired the atopic dermatitis-like phenotype (the spongiosis like intercellular spaces) in the IL-4/IL-13-induced AD-like skin equivalent model[1].
Dipotassium glycyrrhizinate (0-100 μM, 24 h) inhibits Sunitinib-induced autophagy, cardiomyocyte death in CCC-HEH-2 cells[4].
Dipotassium glycyrrhizinate (150 mg/kg, i.p.) reduces plasma glucose and increases plasma GLP-1 in Streptozotocin (65 mg/kg, i.p.) induced type 1-like diabetic rats[2].
Dipotassium glycyrrhizinate (50 mg/kg, i.p., once daily for 4 weeks) inhibits thyroiditis in the Iodine-induced murine model of autoimmune thyroiditis[3].
Dipotassium glycyrrhizinate (50-200 mg/kg, i.p.,) inhibits Bleomycin (HY-108345)-induced pulmonary fibrosis IN rats[5].
| Catalog Number | R063637 |
| CAS Number | 68797-35-3 |
| Synonyms | dipotassium;(2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate |
| Molecular Formula | C42H60K2O16 |
| Purity | ≥95% |
| InChI | InChI=1S/C42H62O16.2K/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50;;/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54);;/q;2*+1/p-2/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+;;/m0../s1 |
| InChIKey | BIVBRWYINDPWKA-VLQRKCJKSA-L |
| SMILES | CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)[O-])O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)[O-])C)C)C)C.[K+].[K+] |
| Reference | [1]. Lee SH, et al. Ameliorating effect of dipotassium glycyrrhizinate on an IL-4- and IL-13-induced atopic dermatitis-like skin-equivalent model. Arch Dermatol Res. 2019 Mar;311(2):131-140. [2]. Wang LY, et al. Glycyrrhizic acid increases glucagon like peptide-1 secretion via TGR5 activation in type 1-like diabetic rats. Biomed Pharmacother. 2017 Nov;95:599-604. [3]. Li C, et al. Glycyrrhizin, a Direct HMGB1 Antagonist, Ameliorates Inflammatory Infiltration in a Model of Autoimmune Thyroiditis via Inhibition of TLR2-HMGB1 Signaling. Thyroid. 2017 May;27(5):722-731. [4]. Xu Z, et al. Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib. Autophagy. 2022 May;18(5):1152-1173. [5]. Gao L, et al. Glycyrrhizic acid alleviates bleomycin-induced pulmonary fibrosis in rats. Front Pharmacol. 2015 Oct 1;6:215. |
